CERo Total Current Liabilities from 2010 to 2024
| CEROW Stock | 0.02 0.0003 1.54% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 5.2 M | Current Value 4.9 M | Quarterly Volatility 7.9 M |
Check CERo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CERo Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 121.5 K, Interest Income of 121.5 K or Depreciation And Amortization of 2.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. CERo financial statements analysis is a perfect complement when working with CERo Therapeutics Valuation or Volatility modules.
CERo |
Latest CERo Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of CERo Therapeutics Holdings over the last few years. Total Current Liabilities is an item on CERo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CERo Therapeutics Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. CERo Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CERo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
CERo Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,800,892 | |
| Geometric Mean | 243,282 | |
| Coefficient Of Variation | 282.87 | |
| Mean Deviation | 4,324,512 | |
| Median | 98,072 | |
| Standard Deviation | 7,922,932 | |
| Sample Variance | 62.8T | |
| Range | 30.7M | |
| R-Value | 0.44 | |
| Mean Square Error | 54.6T | |
| R-Squared | 0.19 | |
| Significance | 0.10 | |
| Slope | 776,501 | |
| Total Sum of Squares | 878.8T |
CERo Total Current Liabilities History
About CERo Therapeutics Financial Statements
CERo Therapeutics investors use historical fundamental indicators, such as CERo Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CERo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 5.2 M | 4.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.